Cargando…

Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study

BACKGROUND: Sivelestat is a neutrophil elastase inhibitor (NEI) with positive impact on the respiratory complications in thoracic surgery. Based on the findings of a recent study, NEI may have a good response for avoiding ischemia reperfusion injury in liver resection. OBJECTIVES: The current study...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Shintaro, Takayama, Tadatoshi, Moriguchi, Masamichi, Hayashi, Yuki, Mitsuka, Yusuke, Yoshida, Nao, Higaki, Tokio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716668/
https://www.ncbi.nlm.nih.gov/pubmed/26834789
http://dx.doi.org/10.5812/hepatmon.31235
_version_ 1782410568924135424
author Yamazaki, Shintaro
Takayama, Tadatoshi
Moriguchi, Masamichi
Hayashi, Yuki
Mitsuka, Yusuke
Yoshida, Nao
Higaki, Tokio
author_facet Yamazaki, Shintaro
Takayama, Tadatoshi
Moriguchi, Masamichi
Hayashi, Yuki
Mitsuka, Yusuke
Yoshida, Nao
Higaki, Tokio
author_sort Yamazaki, Shintaro
collection PubMed
description BACKGROUND: Sivelestat is a neutrophil elastase inhibitor (NEI) with positive impact on the respiratory complications in thoracic surgery. Based on the findings of a recent study, NEI may have a good response for avoiding ischemia reperfusion injury in liver resection. OBJECTIVES: The current study aimed to examine the impact of NEI on the postoperative outcomes after liver resection. PATIENTS AND METHODS: The data were collected from 374 consecutive patients scheduled to undergo liver resection. Seven perioperative variables were matched on the basis of the patients’ background. Then, the NEI (n = 61) and control (n = 61) groups were compared. NEI was administered at a dose of 0.2 mg/kg/h for three days from the postoperative day 0 (POD0). The liver function, coagulation activity, inflammatory response, respiratory complications, and overall complications were compared. RESULTS: The levels of serum interleukin-6 (NEI group: 113 pg/mL [26.9 - 522.0] vs. control group: 174 [28.6 - 1040.6], P < 0.01) and C-reactive protein (CRP) (2.9 IU/L [range: 0.1 - 8.6] vs. 4.11 [0.3 - 13.8], P = 0.01) on the first postoperative day (POD1) and the alveolar-arterial oxygen tension difference (32.3 Torr [-28.6 - 132.3] vs. 46.6 [-11.2 - 251.6], P = 0.04) on the third postoperative day (POD3) were significantly lower in the NEI group than the control group. The rate of pleural effusion was significantly lower in the NEI group compared to that of the control group [13 patients (21.3%) vs. 23 (37.7%), P = 0.04]. However, the coagulation activities (P = 0.68), liver function (P = 0.69), non-respiratory complications (P = 0.84), and overall complications (P = 0.71) did not differ significantly between the groups. CONCLUSIONS: Intravenous NEI administration had positive impact on the postoperative inflammatory response and oxygenation while it did not affect either coagulation or the liver function, as well as severe grade complications following resection.
format Online
Article
Text
id pubmed-4716668
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-47166682016-01-29 Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study Yamazaki, Shintaro Takayama, Tadatoshi Moriguchi, Masamichi Hayashi, Yuki Mitsuka, Yusuke Yoshida, Nao Higaki, Tokio Hepat Mon Research Article BACKGROUND: Sivelestat is a neutrophil elastase inhibitor (NEI) with positive impact on the respiratory complications in thoracic surgery. Based on the findings of a recent study, NEI may have a good response for avoiding ischemia reperfusion injury in liver resection. OBJECTIVES: The current study aimed to examine the impact of NEI on the postoperative outcomes after liver resection. PATIENTS AND METHODS: The data were collected from 374 consecutive patients scheduled to undergo liver resection. Seven perioperative variables were matched on the basis of the patients’ background. Then, the NEI (n = 61) and control (n = 61) groups were compared. NEI was administered at a dose of 0.2 mg/kg/h for three days from the postoperative day 0 (POD0). The liver function, coagulation activity, inflammatory response, respiratory complications, and overall complications were compared. RESULTS: The levels of serum interleukin-6 (NEI group: 113 pg/mL [26.9 - 522.0] vs. control group: 174 [28.6 - 1040.6], P < 0.01) and C-reactive protein (CRP) (2.9 IU/L [range: 0.1 - 8.6] vs. 4.11 [0.3 - 13.8], P = 0.01) on the first postoperative day (POD1) and the alveolar-arterial oxygen tension difference (32.3 Torr [-28.6 - 132.3] vs. 46.6 [-11.2 - 251.6], P = 0.04) on the third postoperative day (POD3) were significantly lower in the NEI group than the control group. The rate of pleural effusion was significantly lower in the NEI group compared to that of the control group [13 patients (21.3%) vs. 23 (37.7%), P = 0.04]. However, the coagulation activities (P = 0.68), liver function (P = 0.69), non-respiratory complications (P = 0.84), and overall complications (P = 0.71) did not differ significantly between the groups. CONCLUSIONS: Intravenous NEI administration had positive impact on the postoperative inflammatory response and oxygenation while it did not affect either coagulation or the liver function, as well as severe grade complications following resection. Kowsar 2015-11-07 /pmc/articles/PMC4716668/ /pubmed/26834789 http://dx.doi.org/10.5812/hepatmon.31235 Text en Copyright © 2015, Kowsar Corp. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Yamazaki, Shintaro
Takayama, Tadatoshi
Moriguchi, Masamichi
Hayashi, Yuki
Mitsuka, Yusuke
Yoshida, Nao
Higaki, Tokio
Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study
title Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study
title_full Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study
title_fullStr Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study
title_full_unstemmed Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study
title_short Neutrophil Elastase Inhibitor Following Liver Resection: A Matched Cohort Study
title_sort neutrophil elastase inhibitor following liver resection: a matched cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716668/
https://www.ncbi.nlm.nih.gov/pubmed/26834789
http://dx.doi.org/10.5812/hepatmon.31235
work_keys_str_mv AT yamazakishintaro neutrophilelastaseinhibitorfollowingliverresectionamatchedcohortstudy
AT takayamatadatoshi neutrophilelastaseinhibitorfollowingliverresectionamatchedcohortstudy
AT moriguchimasamichi neutrophilelastaseinhibitorfollowingliverresectionamatchedcohortstudy
AT hayashiyuki neutrophilelastaseinhibitorfollowingliverresectionamatchedcohortstudy
AT mitsukayusuke neutrophilelastaseinhibitorfollowingliverresectionamatchedcohortstudy
AT yoshidanao neutrophilelastaseinhibitorfollowingliverresectionamatchedcohortstudy
AT higakitokio neutrophilelastaseinhibitorfollowingliverresectionamatchedcohortstudy